SEC Form 4 · accession 0001104659-17-026371
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory S Patrick
Officer — VP, Chief Financial Officer
Period of report
Apr 24, 2017
Accepted (ET)
Apr 26, 2017 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 24, 2017 | M | 50,000 | $5.88 | A | 54,221 | D | |
| Common StockF2 | Apr 24, 2017 | S | 54,000 | $32.368 | D | 221 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $5.88 | Apr 24, 2017 | M | 50,000 | D | — | Dec 16, 2021 | Common Stock | 50,000 | 55,000 | D |
Explanation of responses
- F1Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 22, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.2500 to $32.7500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The option became exercisable in four equal installments beginning on December 30, 2012, which was the first anniversary of the date on which the option was granted.